KIR3DL3/CD158z Antibody (CH21) [PE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-21499PE
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Immunoprecipitation
Label
PE (Excitation = 488 nm, Emission = 575 nm)
Antibody Source
Monoclonal Mouse IgG2A Clone # CH21
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Human KIR3DL3/CD158z transfectants
Epitope
The mouse monoclonal antibody CH21 recognizes an extracellular epitope of human KIR3DL3/CD158z.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications for KIR3DL3/CD158z Antibody (CH21) [PE]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: KIR3DL3/CD158z
Long Name
Killer Cell Immunoglobulin-like Receptor, Three Domain Long Cytoplasmic Tail, 3
Alternate Names
CD158z, KIR3DL7, KIR44, KIRC1
Gene Symbol
KIR3DL3
Additional KIR3DL3/CD158z Products
Product Documents for KIR3DL3/CD158z Antibody (CH21) [PE]
Product Specific Notices for KIR3DL3/CD158z Antibody (CH21) [PE]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...